Hematology

Clinical Trial NameClinical Trial Full TitlePrincipal InvestigatorProject site statusClinical trials gov number
2215-CL-0301A Phase 3 Open-label, Multicenter, Randomized Study of ASP2215 versus Salvage Chemotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) with FLT3 MutationLeber, Dr BrianOpenNCT02421939
CINC424B2001XAn open-label, multi-center, Expanded Treatment Protocol (ETP) of ruxolitinib in patients with Polycythemia Vera who are Hydroxyurea resistant or intolerant and for whom no treatment alternatives are available.Leber, Dr BrianOpenNCT02292446
MEDALISTA Phase 3, Double-blind, Randomized Study to Compare the Efficacy and Safety of Luspatercept (ACE-536-MDS-001) Versus Placebo for the Treatment of Anemia Due to IPSS-R Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes in Subjects with Ring Sideroblasts Who Require Red Blood Cell Transfusions (MEDALIST)Leber, Dr BrianOpenNCT02631070
M15-531A Randomized Phase 2 Study Evaluating the Safety, Pharmacokinetics and Efficacy of Venetoclax in Combination with Azacitidine Compared with Azacitidine Alone in Subjects with Treatment-Naïve Higher-Risk Myelodysplastic Syndromes (MDS)Leber, Dr BrianOpenNCT02942290
AZA-MDS-003A phase 3, multicentre, randomized, double-blind study to compare with efficacy and safety of oral azacitidine plus best supportive care versus placebo plus best supportive care in subjects with red blood cell transfusion-dependent anemia and thrombocytopenia due to IPSS lower-risk myelodysplatic syndromesLeber, Dr BrianOpenNCT01566695
INSPIREA Phase III, International, Randomized, Controlled Study of Rigosertib versus Physician’s Choice of Treatment in Patients with Myelodysplastic Syndrome after Failure of a Hypomethylating AgentLeber, Dr BrianOpenNCT02562443
OZM-056Treatment-free Remission Accomplished with Dasatinib in Patients with CMLLeber, Dr BrianOpenNCT02268370
SGI-110-07A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML) Previously Treated with Hypomethylating AgentsLeber, Dr BrianOpenNCT02907359
M15-550Open-label, single arm, phase 3b, multi-center study evaluating the efficacy of Venetoclax (ABT-199) in relapsed/refractory subjects with chronic lymphocytic leukemia (CLL) including those with the 17p deletion or TP53 mutation OR those who are refractory or intolerant to B-cell receptor inhibitorsLeber, Dr BrianOpenNCT02756611
WO29519A MULTICENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PHASE III STUDY OF IDASANUTLIN, AN MDM2 ANTAGONIST, WITH CYTARABINE VERSUS CYTARABINE PLUS PLACEBO IN PATIENTS WITH RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA (AML)Leber, Dr BrianOpenNCT02545283
LY.17A MULTI-STAGE RANDOMIZED PHASE II STUDY OF NOVEL COMBINATION THERAPY IN THE TREATMENT OF RELAPSED AND REFRACTORY AGGRESSIVE B-CELL LYMPHOMAFraser, Dr GraemeOn holdNCT02436707
Download PDF